(News Bulletin 247) – Novo Nordisk, the world leader in the treatment of diabetes, announced Thursday first quarter results that exceeded expectations, but some unexpected elements came to worry the market.
The Danish group’s operating profit came out at 25 billion Danish kroner in the first three months of 2023, up 31% compared to last year and slightly above the consensus which was established at 23 ,7 billions.
Turnover amounted to 53.4 billion crowns, up 25% and again above the consensus of 52.2 billion.
Novo – which raised its annual targets last month – said it was particularly encouraged by the level of prescriptions for its new obesity drug, Wegovy, in the United States.
But the group also pointed out that the strong growth of the product, as well as the high demand for the antidiabetic Ozempic, raised fears of future shortages due to the limited production capacities it currently has.
As a result, the title fell by 4.5% on Thursday on the Copenhagen Stock Exchange in the wake of this publication.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
